



May 14, 2020 (Updated June 19, 2020)

Web Announcement 2197

Attention Provider Types 11 (Hospital, Inpatient), 20 (Physician, M.D., Osteopath, D.O.), 24 (Advanced Practice Registered Nurses), 75 (Critical Access Hospital (CAH), Inpatient), 77 (Physician's Assistant) and 28 (Pharmacy):

Remdesivir Authorized for Novel Coronavirus (COVID-19) Treatment

Remdesivir is an investigational drug that has not been approved by the Food and Drug Administration (FDA) for any indication; however, the FDA has granted Emergency Use Authorization (EUA) for the treatment of Novel Coronavirus (COVID-19). Effective with dates of service on or after May 6, 2020, remdesivir is authorized for use for the treatment of hospitalized Nevada Medicaid recipients with an oxygen saturation of $\leq 94\%$ on room air or requiring supplemental oxygen, mechanical ventilation and/or extracorporeal membrane oxygenation.

Gilead Sciences is the biopharmaceutical company that developed the drug and is currently offering the medication free of charge.

The remdesivir covered by this EUA is only authorized for treatment administered in an inpatient hospital setting via intravenous (IV) infusion by a healthcare provider. Therefore, this medication is being restricted to hospitalized recipients per the FDA EUA. Pharmacy point of sale (POS) and outpatient physician-administered drug (PAD) claims for this medication are not allowed.

Coverage limitations will be re-reviewed when additional information is available or when this EUA is terminated.